טוען...
CETP inhibition with Anacetrapib Decreases Fractional Clearance Rates of HDL Apolipoprotein A-I and Plasma CETP
OBJECTIVE: Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of HDL-C, apoA-I, apoA-II, and CETP. The mechanisms responsible for these treatment-related increases in apolipoproteins and plasma CETP are unknown. We performed a randomized,...
שמור ב:
| הוצא לאור ב: | Arterioscler Thromb Vasc Biol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4911016/ https://ncbi.nlm.nih.gov/pubmed/26966279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.115.306680 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|